Article Text

Download PDFPDF

Review: restricted dietary salt intake can reduce blood pressure but does not reduce death or cardiovascular morbidity
  1. Bruce Arroll, MBChB, MHSc, PhD
  1. University of Auckland
 Auckland, New Zealand

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: In people with normal and elevated blood pressure (BP), does a reduction in dietary salt decrease blood pressure, death, or cardiovascular events?

    Data sources

    Studies were identified by searching the Cochrane Library, Medline, and EMBASE/Excerpta Medica; reviewing bibliographies or relevant studies; and contacting authors.

    Study selection

    2 reviewers independently selected randomised controlled trials (RCTs) that compared interventions designed to reduce salt intake with placebo or no active intervention in adults (≥16 y) with normal or high BP. Institutionalised, acutely ill, or pregnant people were excluded.

    Data extraction

    2 reviewers independently assessed the quality of RCTs (randomisation method, allocation concealment, blinding, and losses to follow up) and extracted data on patient characteristics, interventions and type of controls, and outcomes (including mortality, cardiovascular events, dropouts, and BP levels).

    Main results

    11 RCTs met the selection criteria. 3 RCTs included normotensive participants (2326 participants, mean age 40 y), 5 RCTs included untreated hypertensive participants (387 participants, 16–64 y of age), and 3 RCTs included treated hypertensive participants (801 participants, 55–67 y of age). Follow up ranged from 6 months to 7 years. Dietary salt restriction reduced systolic and diastolic BP at 6–12 months (7 RCTs) and systolic BP at 13–60 months (4 RCTs). Groups did not differ in the number of dropouts, mortality, cardiovascular morbidity, diastolic BP at 13–60 months (table), or BP at >60 months.

    Dietary salt restriction v control for normal or high blood pressure*


    In people with normal or high blood pressure, dietary salt restriction reduces blood pressure at 6–12 months. In the few trials reporting on mortality and cardiovascular morbidity, no difference was seen.


    The small reduction in BP with salt restriction reported in the review by Hooper et al is unimpressive. It is interesting, however, that some patients were able to stop their antihypertensive medication and use salt restriction as an alternative, without any deterioration in their BP control. The fact that this review could show no benefit in cardiovascular events is not surprising as there were only 17 deaths in the whole review and they were equally distributed between intervention and control groups.

    The average sodium intake in developed countries is about 150 mmol/day. Most dietary sodium comes from processed food (eg, bread, cheese). The average Yanomamo Indian from the Brazilian forest has an intake of just 1 mmol/day and an average adult BP of 96/61 mm Hg.1 Such low levels of intake are not realistic in developed countries, and intakes of no higher than 50–100 mmol/day are recommended to reduce BP. Sodium restriction is not popular and should only be recommended to the few who are determined to stay off medication or at least stay on the lowest dose possible. They will need to make their own bread or find a supply of low or no sodium bread. It will take them about 6 weeks to adapt to the taste in their food.

    Patients may be more interested in increasing their aerobic physical activity, which can result in reductions of BP of about 4 mm Hg systolic and 3 mm Hg diastolic, or losing weight with a 2–4 kg weight loss resulting in a 1 mm Hg reduction in systolic BP. Others may prefer to reduce their alcohol intake because each drink reduction per day results in systolic and diastolic reductions of about 1 mm Hg.



    • Source of funding: North West Research and Development Training Fellowship.

    • For correspondence: Ms L Hooper, University Dental Hospital of Manchester, Manchester, UK. lee.hooper{at}